Loading
A phase 2 trial of HLX43 in oesophageal cancer, run by Shanghai Henlius Biotech, now recruiting.
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy is a phase 2 interventional study registered as NCT06769113 by Shanghai Henlius Biotech, with 102 participants planned, started 2025-01-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: HLX43.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal squamous cell carcinoma and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/